Evidence map›Paper›PMID 41845484›Full record

ArticleJournal of biological engineering2026

Triphenylphosphine bromide enhances the effect of nano-micellar drug delivery system loaded with ROS inhibitor TEMPO on acute lung injury.

Jing Wang, Lisheng Xu, Wanrong Li, Fang Zhao, Yang Yang, Lingling Shan, Linyan Xin, Weiwei Wang

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of biological engineering, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Jing WangSchool of Biology and Food Engineering, Institute of Pharmaceutical Pharmacology Research Center, Suzhou University, Suzhou, Anhui, China. hjwang@ahszu.edu.cn.
Lisheng XuSchool of Biology and Food Engineering, Institute of Pharmaceutical Pharmacology Research Center, Suzhou University, Suzhou, Anhui, China.
Wanrong LiSchool of Biology and Food Engineering, Institute of Pharmaceutical Pharmacology Research Center, Suzhou University, Suzhou, Anhui, China.
Fang ZhaoSchool of Biology and Food Engineering, Institute of Pharmaceutical Pharmacology Research Center, Suzhou University, Suzhou, Anhui, China.
Yang YangSchool of Biology and Food Engineering, Institute of Pharmaceutical Pharmacology Research Center, Suzhou University, Suzhou, Anhui, China.
Lingling ShanSchool of Biology and Food Engineering, Institute of Pharmaceutical Pharmacology Research Center, Suzhou University, Suzhou, Anhui, China.
Linyan XinYancheng First People's Hospital Pharmacy Department, Yanchen, Anhui, China.
Weiwei WangSchool of Biology and Food Engineering, Institute of Pharmaceutical Pharmacology Research Center, Suzhou University, Suzhou, Anhui, China. wwthebest@sina.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundSepsis acute lung injury (ALI) is one of the common complications in sepsis. The molecular mechanism and treatment methods of acute lung injury in sepsis are unknown.

aimThe aim of this study was to prepare triphenylphosphine bromide (TPP)-polyethylene glycol-b-polycaprolactone (PEG-PCL) nano-micelles for the delivery of ROS inhibitor (TEMPO) [TEMPO@PP-PEG-PCL] in the treatment of acute lung injury (ALI).

methodsTEMPO@TPP-PEG-PCL were prepared. The particle size, zeta potential and morphology of the TEMPO@TPP-PEG-PCL were determined. The stability, in vitro release, pharmacokinetics and critical micelle concentration of the TEMPO@TPP-PEG-PCL were determined. Lipopolysaccharide (LPS) was used to establish the models of ALI. in vivo and in vitro. Immunohistochemistry, western blot and immunofluorescence were used to evaluate the effects of TEMPO@TPP-PEG-PCL on mtDNA-cGAS-STING signal pathway in ALI.

resultsThe particle size of TEMPO@TPP-PEG-PCL was (22.7 ± 0.3) nm and the zeta potential was (24.3 ± 0.4) mV. The transmission electron microscope showed that TEMPO@TPP-PEG-PCL were regular spheres. The results of fluorescence showed that TEMPO@TPP-PEG-PCL promoted the cellular uptake of drugs. Compared with TEMPO, TEMPO@TPP-PEG-PCL significantly decreased the level of intracellular ROS (P < 0.01) and mtDNA (P < 0.01) and the protein expressions of cGAS-STING-IRF3/NF-κB signal pathway(P < 0.01).

conclusionsOur results demonstrated that TEMPO@TPP-PEG-PCL were successfully prepared to deliver TEMPO for treatment of ALI. The mechanism was related to the regulation of cGAS-STING-IRF3/NF-κB signaling pathway.

Indexed as

ALIcGAS-STINGmtDNAROSTPP-PEG-PCL

Identifiers

PMID41845484
PMCPMC13107680

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.